Phospholipase C Gamma 2 (PLCG2) Gene Mutation Analysis
The PLCG2 gene is located in the long (q) arm of chromosome 16 at position 23.3 and encodes a transmembrane signaling enzyme (PLCγ2) that catalyzes the conversion of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate to 1D-myo-inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) using calcium as a cofactor. IP3 and DAG are second messenger molecules important for transmitting signals from growth factor receptors and immune system receptors across the cell membrane. PLCγ2 is predominantly expressed in the bone marrow and lymphoid organs. Mutations in PLCG2 are associated with inherited immune disorders such as PLCG2-associated antibody deficiency and immune dysregulation (PLAID) and autoinflammatory PLCG2-associated antibody deficiency and immune dysregulation (APLAID).
In PLAID intragenic deletions in PLCG2 result in the production of an altered PLCγ2 enzyme affecting its function. This condition is inherited in an autosomal dominant manner and heterozygotes are characterized by the development of cutaneous urticaria, erythema, and pruritis in response to cold exposure. Affected individuals have variable additional immunologic defects, including antibody deficiency, decreased numbers of B-cells, defective B-cells, increased susceptibility to infection, and increased risk of autoimmune disorders. In APLAID, missense mutations in PLCG2 result in production of a defective PLCγ2 enzyme, which causes autoinflammation. It is an autosomal dominant systemic disorder characterized by recurrent blistering skin lesions with a dense inflammatory infiltrate and variable involvement of other tissues, including joints, the eye, and the gastrointestinal tract. Affected individuals have a mild humoral immune deficiency associated with recurrent sinopulmonary infections, but no evidence of circulating autoantibodies. Somatic mutations in the PLCG2 gene includes missense, nonsense, silent, frameshift deletions and insertions, and in-frame deletions in endometrial cancer, intestinal cancer, and parathyroid cancer. PLCG2 is immediately downstream of Bruton's Tyrosine Kinase (BTK) in B-cell regulation pathways. Mutations in PLCG2 are also associated with acquired or secondary resistance to ibrutinib arising after initial response in chronic lymphocytic leukemia (CLL).
- As an aid in diagnosis of PLCG2-associated antibody deficiency and immune dysregulation (PLAID)
- As an aid in diagnosis of autoinflammatory PLCG2-associated antibody deficiency and immune dysregulation (APLAID)
- Evaluate an initial response to ibrutinib in chronic lymphocytic leukemia (CLL)
- Carrier screening for family members at risk
Mutation or pathogenic variants in PLCG2 gene might support diagnosis of of PLCG2-associated antibody deficiency and immune dysregulation. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative for mutations analyzed (No pathogenic variant or mutation detected)
Whole blood (EDTA), bone marrow.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Front Immunol. 2018;9: 2863. [PMID: 30619256]
- Leukemia. 2017 Jul;31(7):1645-1647. [PMID: 28366935]
- Alzheimers Res Ther. 2019;11: 16. [PMID: 30711010]
- J Clin Immunol. 2015 Aug;35(6):527-30. [PMID: 26206677]
- Am J Hum Genet. 2012 Oct 5;91(4):713-20. [PMID: 23000145]
- J Biol Chem. 2009;284: 23083-93. [PMID: 19531496]
- Genomics. 1995 Jan 1;25(1):29-35. [PMID: 7774933]
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/PLCG2#